Clinical and Molecular Study of Various Myeloproliferative Neoplasms MPNs to Understand Disease and Improve Treatment

What this Trial Is About

Researchers are collecting clinical and molecular information from patients diagnosed with various types of myeloproliferative neoplasms MPNs, a group of rare blood cancers where bone marrow cells develop abnormally. This observational registry aims to better understand these diseases by gathering data over time to help improve patient treatment and outcomes. It will also serve as a resource for future studies related to MPNs. The registry collects information from patients diagnosed with MPNs such as atypical chronic myeloid leukemia, chronic eosinophilic leukemia, chronic myelomonocytic leukemia, essential thrombocythemia, mastocytosis, primary myelofibrosis, and others. Both past and ongoing clinical data, molecular profiles, treatment details, complications, symptom assessments, and survival outcomes are gathered at different points during the disease course up to 10 years. Participants provide written consent to have their clinical information collected and stored in a database. Data collected includes disease characteristics, treatment types, blood tests, genetic testing, symptom questionnaires, and complications from treatments or disease progression. Researchers review survival status and disease changes annually or when the disease transforms, with follow-up continuing for up to 10 years.

Myeloproliferative Neoplasms (MPNs) Patient Registry